Brainsway Ltd.
BWAY
Positions held
Your positionsBWAY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $461.70M | Enterprise value | $405.31M | Trailing P/E | 49.87 | Forward P/E | 22.64 |
| PEG | — | Price / book | 5.81 | Beta | 0.10 | Dividend yield | 0.00% |
| Revenue growth | 35.4% | Earnings growth | 59.8% | Gross margin | 75.3% | Operating margin | 14.0% |
| Profit margin | 15.6% | ROE | 12.8% | ROA | 4.0% | Debt / equity | 0.09 |
| Current ratio | 3.59 | Free cash flow | -$6.16M | Analyst recommendation | none | Mean target | $19.27 |
| 52w high | $17.40 | 52w low | $7.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $17.1M | $15.5M | $14.5M | $13.5M | $12.6M |
| Op margin | 14.0% | 12.9% | 13.2% | 9.3% | 4.6% |
| Net income | $2.7M | $2.3M | $2.9M | $1.6M | $2.0M |
| Gross margin | 74.6% | 75.2% | 76.4% | 75.2% | 75.2% |
| Gross profit | $12.8M | $11.7M | $11.1M | $10.2M | $9.5M |
| Operating income | $2.4M | $2.0M | $1.9M | $1.3M | $0.6M |
- Revenue +10% vs prior quarter ($17M vs $16M).
- Gross margin 74.6% (was 75.2% prior quarter).
- Operating margin expanded to 14%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $52.2M | $41.0M | $31.8M | $27.2M | — |
| Op margin | 8.3% | 3.4% | -15.6% | -46.7% | — |
| Net income | $7.6M | $2.9M | -$4.2M | -$13.3M | — |
| Gross margin | 75.4% | 74.6% | 73.9% | 73.8% | — |
| Gross profit | $39.4M | $30.6M | $23.5M | $20.0M | — |
| Operating income | $4.3M | $1.4M | -$5.0M | -$12.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-11 · BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore
2026-09-09 · Are Options Traders Betting on a Big Move in Brainsway Stock?
2026-08-27 · Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
2026-08-27 · BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
2026-08-17 · Brainsway (BWAY) Upgraded to Buy: Here's Why
2026-08-17 · Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
2026-08-13 · Brainsway Q2 Earnings Call Highlights
2026-08-12 · BrainsWay Ltd (BRSYF) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% to $17. ...
2026-08-12 · BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-11 · Earnings To Watch: BrainsWay Ltd (BWAY) Q2 2026 -- GF Value Sees 35% Downside
2026-07-29 · BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
Price (daily)
Full chart · RSI · MACD · patterns